Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...

Jared Holz, Mizuho Securities America healthcare sector strategist, joins 'Squawk Box' to break down the quarterly earnings ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 ...